MNKD MannKind Corporation

1.98
+0.04  (2%)
Previous Close 1.94
Open 1.95
Price To book -0.94
Market Cap 207271780
Shares 104,682,717
Volume 2,139,688
Short Ratio 7.43
Av. Daily Volume 2,745,362

SEC filingsSee all SEC filings

  1. 8-K - Current report 171078018
  2. 8-K - Current report 171071671
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011550
  4. 8-K - Current report 171011527
  5. 8-K - Current report 171011524

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes

Latest News

  1. Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?
  2. Believe It or Not, MannKind Is Now One of the Hottest Biotech Stocks on the Market
  3. With MannKind Down Over 90%, Nvidia Enables Nate Pile To Beat The Market
  4. Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation
  5. A Small Cap Stock Making Big Cap Waves
  6. MannKind Responds to Hurricane Harvey Devastation with Afrezza® Donation
  7. MannKind, Can Internal Sales Push Improve Adoption of Afrezza?
  8. MannKind Corporation Relocates Headquarters to Westlake Village
  9. MannKind Corporation to Present at Upcoming Conferences
  10. 3 Stocks Capitalizing Off Positive Market Momentum On Wednesday
  11. Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind Corporation
  12. Options Traders Expect Huge Moves in MannKind Corporation (MNKD) Stock
  13. Edited Transcript of MNKD earnings conference call or presentation 7-Aug-17 9:00pm GMT
  14. Featured Company News – MannKind and One Drop Announce Collaboration to Deliver a Unified Solution for Diabetes Patients
  15. MannKind Corporation (MNKD) Shares Up Despite Earnings Miss
  16. 5 Things You'll Really Want to Know from MannKind's Q2 Update
  17. MannKind reports 2Q loss
  18. MannKind Corporation Reports 2017 Second Quarter Financial Results
  19. Investor Network: MannKind Corporation to Host Earnings Call
  20. MannKind and One Drop Partner to Launch the A-ONE Clinical Trial

SEC Filings

  1. 8-K - Current report 171078018
  2. 8-K - Current report 171071671
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011550
  4. 8-K - Current report 171011527
  5. 8-K - Current report 171011524
  6. 8-K - Current report 17967896
  7. EFFECT - Notice of Effectiveness 17966522
  8. S-1 - General form for registration of securities under the Securities Act of 1933 17943761
  9. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 17943750
  10. 8-K - Current report 17936935